Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia

<p>Abstract</p> <p>Background</p> <p>To retrospectively access the outcome and toxicity of a total skin electron beam therapy (TSEBT) in patients with cutaneous lymphoma (CL) or leukemia.</p> <p>Patients and methods</p> <p>Treatment results of 25...

Full description

Bibliographic Details
Main Authors: Hauswald Henrik, Zwicker Felix, Rochet Nathalie, Uhl Matthias, Hensley Frank, Debus Jürgen, Herfarth Klaus, Bischof Marc
Format: Article
Language:English
Published: BMC 2012-07-01
Series:Radiation Oncology
Subjects:
Online Access:http://www.ro-journal.com/content/7/1/118
id doaj-b44672d95f5849318032f514bd942d7b
record_format Article
spelling doaj-b44672d95f5849318032f514bd942d7b2020-11-24T21:00:19ZengBMCRadiation Oncology1748-717X2012-07-017111810.1186/1748-717X-7-118Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemiaHauswald HenrikZwicker FelixRochet NathalieUhl MatthiasHensley FrankDebus JürgenHerfarth KlausBischof Marc<p>Abstract</p> <p>Background</p> <p>To retrospectively access the outcome and toxicity of a total skin electron beam therapy (TSEBT) in patients with cutaneous lymphoma (CL) or leukemia.</p> <p>Patients and methods</p> <p>Treatment results of 25 patients (median age 63 years; 5 female, 20 male) with cutaneous manifestations of advanced and therapy-refractory CL (n = 21; T-cell lymphomas n = 18, B-cell lymphomas n = 3) stage IIB-IV or leukemia (n = 4; AML n = 2, CLL n = 1, PDC n = 1) treated between 1993 and 2010 were reviewed. All patients were symptomatic. The median total dose was 29Gy, applied in 29 fractions of median 1 Gy each.</p> <p>Results</p> <p>The median follow-up was 10 months. Palliation was achieved in 23 patients (92%). A clinical complete response was documented in 13 (52%) and a partial response in 10 patients (40%). The median time to skin progression was 5 months (range 1–18 months) and the actuarial one-year progression-free survival 35%. The median overall survival (OS) after the initiation of TSEBT was 10 months (range 1–46 months) and the actuarial one-year OS 45%. TSEBT related acute adverse events (grade 1 or 2) were observed in all patients during the treatment period. An acute grade 3 epitheliolysis developed in eight patients (32%). Long-term adverse events as a hyperpigmentation of the skin (grade 1 or 2) were documented in 19 patients (76%), and a hypohidrosis in seven patients (28%).</p> <p>Conclusion</p> <p>For palliation of symptomatic cutaneous manifestations of advanced cutaneous lymphoma or leukemia, total skin electron beam therapy is an efficient and well tolerated considerable treatment option.</p> http://www.ro-journal.com/content/7/1/118TSEBTRadiotherapyIrradiationCTCLCutaneous lymphomaLymphomaLeukemia
collection DOAJ
language English
format Article
sources DOAJ
author Hauswald Henrik
Zwicker Felix
Rochet Nathalie
Uhl Matthias
Hensley Frank
Debus Jürgen
Herfarth Klaus
Bischof Marc
spellingShingle Hauswald Henrik
Zwicker Felix
Rochet Nathalie
Uhl Matthias
Hensley Frank
Debus Jürgen
Herfarth Klaus
Bischof Marc
Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia
Radiation Oncology
TSEBT
Radiotherapy
Irradiation
CTCL
Cutaneous lymphoma
Lymphoma
Leukemia
author_facet Hauswald Henrik
Zwicker Felix
Rochet Nathalie
Uhl Matthias
Hensley Frank
Debus Jürgen
Herfarth Klaus
Bischof Marc
author_sort Hauswald Henrik
title Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia
title_short Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia
title_full Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia
title_fullStr Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia
title_full_unstemmed Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia
title_sort total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia
publisher BMC
series Radiation Oncology
issn 1748-717X
publishDate 2012-07-01
description <p>Abstract</p> <p>Background</p> <p>To retrospectively access the outcome and toxicity of a total skin electron beam therapy (TSEBT) in patients with cutaneous lymphoma (CL) or leukemia.</p> <p>Patients and methods</p> <p>Treatment results of 25 patients (median age 63 years; 5 female, 20 male) with cutaneous manifestations of advanced and therapy-refractory CL (n = 21; T-cell lymphomas n = 18, B-cell lymphomas n = 3) stage IIB-IV or leukemia (n = 4; AML n = 2, CLL n = 1, PDC n = 1) treated between 1993 and 2010 were reviewed. All patients were symptomatic. The median total dose was 29Gy, applied in 29 fractions of median 1 Gy each.</p> <p>Results</p> <p>The median follow-up was 10 months. Palliation was achieved in 23 patients (92%). A clinical complete response was documented in 13 (52%) and a partial response in 10 patients (40%). The median time to skin progression was 5 months (range 1–18 months) and the actuarial one-year progression-free survival 35%. The median overall survival (OS) after the initiation of TSEBT was 10 months (range 1–46 months) and the actuarial one-year OS 45%. TSEBT related acute adverse events (grade 1 or 2) were observed in all patients during the treatment period. An acute grade 3 epitheliolysis developed in eight patients (32%). Long-term adverse events as a hyperpigmentation of the skin (grade 1 or 2) were documented in 19 patients (76%), and a hypohidrosis in seven patients (28%).</p> <p>Conclusion</p> <p>For palliation of symptomatic cutaneous manifestations of advanced cutaneous lymphoma or leukemia, total skin electron beam therapy is an efficient and well tolerated considerable treatment option.</p>
topic TSEBT
Radiotherapy
Irradiation
CTCL
Cutaneous lymphoma
Lymphoma
Leukemia
url http://www.ro-journal.com/content/7/1/118
work_keys_str_mv AT hauswaldhenrik totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia
AT zwickerfelix totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia
AT rochetnathalie totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia
AT uhlmatthias totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia
AT hensleyfrank totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia
AT debusjurgen totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia
AT herfarthklaus totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia
AT bischofmarc totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia
_version_ 1716780109752434688